The Efficacy and Safety of Luspatercept in Improving Early Anemia After HSCT

NCT07450313 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

HSCT

Interventions

DRUG: Luspatercept

Sponsor

Institute of Hematology & Blood Diseases Hospital, China